Rituximab for Leucine-Rich Glioma-Inactivated 1 (LGI1) Antibody-Related Super-refractory Status Epilepticus: A Case Report and Literature Review
Year: 2025
Type: article
Study design: Case Report
Abstract: Leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a form of autoimmune encephalitis (AE) that presents with memory loss, faciobrachial dystonic seizures (FBDSs), disorientation, psychiatric symptoms, and hyponatremia. Diagnosis is based on clinical presentation, magnetic resonance imaging (MRI), serum or cerebrospinal fluid (CSF) antibody testing, and electroencephalography (EEG) findings. Most available studies on its clinical features and treatment are limited to case reports and series, highlighting the need for a comprehensive understanding and standardized treatment approach. Herein, we report a 61-year-old Saudi retiree with cognitive decline, recurrent right FBDS, generalized tonic-clonic seizures, and persistent hyponatremia who showed a significant improvement after rituximab therapy.
Source: Cureus
DOI: 10.7759/cureus.81094
Authors: Alawi A Al-Attas, Samar E Eshetaiwe, Mesdah A Alnahdi, Hoda M Nassar, Ahmed H Althobaiti
Institution: King Saud Medical City
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408784253
